Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

MLA

Howard S. Hochster, et al. Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-Line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.c.6531176.v1.

APA

Howard S. Hochster, Andrew M. Lowy, Shay Bellasea, Mai Duong, Marc R. Radke, Dana Backlund Cardin, Ignacio Garrido-Laguna, Jennifer M. Suga, Marcus S. Noel, Jordan Berlin, Michael J. Pishvaian, Florencia Jalikis, Elizabeth M. Swisher, Philip A. Philip, Katherine A. Guthrie, & E. Gabriela Chiorean. (2023). Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. https://doi.org/10.1158/1078-0432.c.6531176.v1

Chicago

Howard S. Hochster, Andrew M. Lowy, Shay Bellasea, Mai Duong, Marc R. Radke, Dana Backlund Cardin, Ignacio Garrido-Laguna, et al. 2023. “Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-Line Treatment of Metastatic Pancreatic Cancer: SWOG S1513,” March. doi:10.1158/1078-0432.c.6531176.v1.